GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
- GSK CEO marks 10th anniversary of drive to eliminate lymphatic filariasis (LF) with donation of one-billionth albendazole tablet and grant to The Carter Center
The announcement was made during a celebration for the 10th anniversary of GSK’s commitment to the Global Program to Eliminate LF at The Carter Center in
A clear example of the company’s long-term commitment, the Global Program to Eliminate LF relies on the donation of two drugs necessary for LF elimination – (albendazole and Mectizan(R), respectively) – from GlaxoSmithKline and Merck & Co., Inc. – in partnership with the World Health Organization (WHO). The program’s goals are two-fold: eliminate LF as a public health problem by 2020; and alleviate physical, social and economic hardship in individuals who have LF-induced disability.
Over the past decade the program, supported by the Global Alliance to Eliminate LF, has become the most rapidly scaled-up drug administration program in public health history. It is on track to be the largest drug donation program ever supported by the pharmaceutical industry. This month the one-billionth albendazole tablet will be donated by GSK. Several countries have completed the 5-year administration program needed to achieve elimination, including
President Carter said, “We stand at the cusp of major breakthroughs in the elimination and eradication of a number of tropical diseases, notably lymphatic filariasis,
Witty confirmed that GSK has begun building a manufacturing line that will result in a four-fold increase in the current global capacity to produce albendazole tablets. The new facility, to be built in Nashik,
About lymphatic filariasis – Lymphatic filariasis, often called elephantiasis, is a parasitic infection spread by mosquitoes that causes grotesque, painful swelling of the limbs, breasts, and genitals. Considered a neglected tropical disease, LF almost exclusively affects the world’s poorest people. Approximately one fifth of the world’s population (1.3 billion people) is at risk of contracting LF and approximately 120 million people in 83 countries are currently infected.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
The Carter Center – A not-for-profit, nongovernmental organization, The Carter Center has helped to improve life for people in more than 70 countries by resolving conflicts; advancing democracy, human rights, and economic opportunity; preventing diseases; improving mental health care; and teaching farmers in developing nations to increase crop production. The Carter Center was founded in 1982 by former U.S. President Jimmy Carter and his wife, Rosalynn, in partnership with
For video content and photography related to this story, please log on to www.thenewsmarket.com/gsk.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk Factors’ in the ‘Business Review’ in the company’ s Annual Report on Form 20-F for 2007.